Safety and efficacy of autoantigen‐specific therapy with 2 doses of alum‐formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial

Objective Treatments have failed to delay or stop the autoimmune process, preceding onset of type 1 diabetes. We investigated if autoantigen‐specific treatment with alum‐formulated glutamate decarboxylase (GAD‐Alum) was safe and affected progression to type 1 diabetes in children with islet autoimmu...

Full description

Saved in:

Bibliographic Details
Published in:	Pediatric diabetes Vol. 19; no. 3; pp. 410 - 419
Main Authors:	Elding Larsson, Helena, Lundgren, Markus, Jonsdottir, Berglind, Cuthbertson, David, Krischer, Jeffrey
Format:	Journal Article
Language:	English
Published:	Former Munksgaard John Wiley & Sons A/S 01.05.2018 John Wiley & Sons, Inc
Subjects:	Aluminum sulfate Autoantibodies Autoimmunity Children Clinical Medicine Clinical trials Diabetes Diabetes mellitus Diabetes mellitus (insulin dependent) Endocrinology and Diabetes Endokrinologi och diabetes GAD‐Alum Glucose Glucose tolerance Glutamate decarboxylase Hematology Immunological tolerance Insulin Insulinoma Intravenous administration Klinisk medicin Medical and Health Sciences Medicin och hälsovetenskap Neuroendocrine tumors Pediatrics Pediatrik prevention Safety Thyroid type 1 diabetes type 1 diabetes autoimmunity GAD-Alum prevention
ISSN:	1399-543X, 1399-5448, 1399-5448
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!